Shuttle Pharmaceuticals Holdings, Inc. 是一家处于临床阶段的制药公司,致力于开发癌症治疗的新疗法。公司总部位于马里兰州盖瑟斯堡,目前有9名全职员工。该公司于2022年8月31日上市。公司专注于改善接受放射治疗(RT)的癌症患者的治疗效果。公司正在开发一系列产品管线,旨在解决癌症治疗方法以及扩展放射治疗的新应用。其候选产品包括Ropidoxuridine(IPdR)、Ropidoxuridine与Tipracil(IPdR/TPI)、SP-1-161、SP-2-225和SP-1-303。Ropidoxuridine(IPdR)是公司的主要候选放射增敏剂,用于与放射治疗联合治疗脑肿瘤(胶质母细胞瘤)和肉瘤。Ropidoxuridine与Tipracil(IPdR/TPI)正在进行直肠癌治疗的临床前开发,作为放射增敏剂使用。SP-1-161是一种临床前主要组蛋白去乙酰化酶(HDAC)抑制剂,属于放射增敏候选产品。SP-2-225是一种临床前IIb类选择性HDAC抑制剂,可影响组蛋白去乙酰化酶HDAC6。
SHPH stock price ended at $0.86 on 星期四, after dropping 4.44%
On the latest trading day Mar 26, 2026, the stock price of SHPH fell by 4.44%, dropping from $0.89 to $0.86. During the session, the stock saw a volatility of 9.30%, with prices oscillating between a daily low of $0.86 and a high of $0.94. On the latest trading day, the trading volume for SHPH rose by 261.4K shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 382.3K shares were traded, with a market value of approximately $4.8M.